{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010850","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.078393+00:00","generated_at":"2026-05-17T16:21:12.877956+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"KALA BIO completes Phase 2b enrollment for KPI-012; cash runway into Q1 2026","bullets":["Net loss $11.2M ($1.71/share) for Q2 2025 vs $9.6M ($3.16) in Q2 2024.","Cash $31.9M as of June 30; expected to fund operations into Q1 2026.","Phase 2b CHASE trial enrolled 79 patients; topline data expected end of September 2025.","R&D expenses $6.2M in Q2, up 17% YoY due to KPI-012 development costs.","Interim CEO says positive results could support a BLA submission to FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010850","json":"https://secwatch.observer/filing/0001558370-25-010850.json","markdown":"https://secwatch.observer/filing/0001558370-25-010850.md","text":"https://secwatch.observer/filing/0001558370-25-010850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837025010850/0001558370-25-010850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837025010850/kala-20250808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:21:12.877956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}